UBS Maintains Buy on Constellium, Lowers Price Target to $35

Benzinga Newsdesk www.benzinga.com Negative 51.9%

Neg 51.9% Neu 0% Pos 0%

UBS analyst Alex Stansbury maintains Constellium (NYSE:CSTM) with a Buy and lowers the price target from $38 to $35.

Comments

No comments yet. Be the first!